Q2 2025 · 13F-HR
GREAT POINT PARTNERS LLCholdings as filed
Filed 2025-08-14 · accession 0001172661-25-003478
$153.8M
Reported value
26
Positions
2025-06-30
Period end
The Brief · GREAT POINT PARTNERS LLC · Q2 2025
AI · grounded in 13F
GREAT POINT PARTNERS LLC established a new position in IONS worth $19.76M. The fund also initiated new stakes in RZLT for $13.53M and AMLX for $12.82M. Additional new positions include LEGN, ABVX, and NGNE. The fund ended the period with 26 positions and total AUM of $153.8M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $19.8M | 12.8% | 500,000 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC | $13.5M | 8.80% | 3,033,462 | Common | SHARED |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $12.8M | 8.34% | 2,000,000 | Common | SHARED |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $12.4M | 8.08% | 350,000 | Common | SHARED |
| 00370M103 | ABVX | ABIVAX SA | $9.9M | 6.42% | 1,291,617 | Common | SHARED |
| 64135M105 | NGNE | NEUROGENE INC | $7.3M | 4.72% | 485,859 | Common | SHARED |
| 00972D105 | AKBA | AKEBIA THERAPEUTICS INC | $7.2M | 4.70% | 1,985,915 | Common | SHARED |
| 30052C107 | EOLS | EVOLUS INC | $6.6M | 4.31% | 720,118 | Common | SHARED |
| 03940C100 | ACLXGBX | ARCELLX INC | $6.6M | 4.28% | 100,000 | Common | SHARED |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $6.3M | 4.07% | 200,000 | Common | SHARED |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $5.5M | 3.60% | 103,848 | Common | SHARED |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $5.0M | 3.24% | 498,054 | Common | SHARED |
| 23282W605 | CYTK | CYTOKINETICS INC | $5.0M | 3.22% | 150,000 | Common | SHARED |
| 45258J102 | IMVT | IMMUNOVANT INC | $4.2M | 2.73% | 262,176 | Common | SHARED |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $3.8M | 2.47% | 796,558 | Common | SHARED |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $3.7M | 2.38% | 323,170 | Common | SHARED |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $3.5M | 2.25% | 1,500,000 | Common | SHARED |
| 23306J309 | DBVT | DBV TECHNOLOGIES S A | $3.4M | 2.23% | 374,679 | Common | SHARED |
| G9TY5A101 | ZURA | ZURA BIO LTD | $3.3M | 2.16% | 3,170,194 | Common | SHARED |
| 91678A107 | UPB | UPSTREAM BIO INC | $3.3M | 2.14% | 300,000 | Common | SHARED |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $3.1M | 2.00% | 4,683,711 | Common | SHARED |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $3.0M | 1.92% | 225,000 | Common | SHARED |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $2.2M | 1.42% | 61,607 | Common | SHARED |
| 74346M406 | PMNEUR | PROMIS NEUROSCIENCES INC | $1.3M | 0.83% | 2,645,128 | Common | SHARED |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $986,000 | 0.64% | 850,000 | Common | SHARED |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $312,026 | 0.20% | 29,381 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.